PTE - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the PolarityTE Inc. Fiscal Year 2019 Earnings Call. Today’s conference is being recorded.

At this time, I would like to turn the conference over to Rich Haerle, Vice-President of Investor Relations. Please go ahead, sir.

Rich Haerle

operator. you, Thank thank fiscal and joining call PolarityTE's Good XXXX you results. discuss year to morning for I'm Vice Rich Haerle, President of Relations. Investor Seaburg, today me which and are of Mann, President, David Paul the COO; Richard Financial With Chief Hague, Executive members includes Officer. team

that would constitute I remind to the Safe Act of forward-looking include provisions statements cause begin discussion expectations, statements these plans Harbor everyone under company's materially caution the Private XXXX. the about and actual for may indicated. differ the we forward-looking future today's and Reform will subject like that of Before risks Litigation that to to from statements are those We Securities prospects uncertainties that purposes results

materially that annual results of Form our from a the variety These Factors” more caption SEC, are to including actual our report current statements forward-looking based differ on due factors are detailed with the in December today's our year with “Risk on the under required fully filings of Any statements ended events the that call for March may expectations XX-K on update today. XX, disclaim obligation XXXX made law. XX, after as to or speak as Thursday, date reflect any today's occur such filed and forward-looking call, this we only except to statements XXXX by circumstances SEC and

I'd like being to highlight to participants is that the recorded. call

the our of in and via conclusion and webcast website will Relations following investors available media available the are to on it call. We making a replay section the be the Investor shortly

any form consent expressed or PolarityTE any retransmission in of the is rebroadcast the written of is call PolarityTE's property and it strictly prohibited. Additionally, without redistribution,

David the turn to President. like Seaburg, now call over would to I

David Seaburg

XXXX namely, commercialization an strategic on everyone transformative joining us of XXXX. earnings Good three call; was fiscal quarter for The for our has team of company which pipeline, positioned priorities the and for PolarityTE exciting prioritization to we all committed the third our thank and you afternoon XXXX believe we a executive remains Rich. the year Thanks SkinTE, today. outlined discipline.

on be questions. these progress our Financial my of then quarter efforts, and financial and will provide on remarks XXXX the Officer, Chief XXXX the fourth The open made and Richard Officer, Operating focus execute our changes I on After then second details Mann, up R&D fiscal and discuss the of commercial strategic fourth adoption our help and Hague Chief quarter accelerate during SkinTE. review priorities to will opening update, our this of will clinical return half some important being by call for will the who and Paul followed trials XXXX PolarityTE's year highlights. call to

effort start commercial took like to by SkinTE. everyone our in then important over June the strategic next making this changes XXXX. reminding to eight that months we We and evaluating I'd leadership spent for

do lot Although pleased we are full take we to SkinTE, market advantage still a with progress. have of for the of opportunity our

ago and significantly effort commercial Our to studies, grow. presentations than months evidence is scientific continues case was through just our short and collection eight posters it of stronger

as interim will such from our studies trial, support of are that of publications, We additional data efforts. and additional growth initiation believe portfolio, catalysts our of property potential DFU number by commercialization our the the near-term we excited clinical intellectual

the force tools sales in building and We successful be with field. are our strong appropriate them the to arming

be through SkinTE in and have we educational increasing are trauma focus through we continue We which big Last quarter to for awareness us great strides of focused a market implemented trauma conferences in speakers to newly programs made will focused said on XXXX. program. create awareness

their national physicians aggregate, educational industry local seven XXXX experiences. and during where speakers to fourth we seven the invested And strategically we trauma peer-to-peer the attended programs share and quarter quarter in In fourth in regional conferences in conferences. were hosted able

continue efforts will through believe market We better accelerated contribute these adoption to the awareness. to

SkinTE to address Q&A during we this forward we wounds. happy this believe Additionally, of and evidence wounds evaluation but provide leveraged drive the chronic trauma are growth in we and the in sales I force in chronic and in messages in targets am detail marketing well-positioned and adoption VLUs for trauma to pilot our supports we of to focus data the incremental our in that have sales the call, of more move portion XXXX. as refined our DFU

to metrics. Let's XX% move grew were quarter in paid to to third our to Total to slide was X% XX user to quarter fourth $XXX,XXX. repeat XX% XXXX as grew down SkinTE XX, XX% The SkinTE commercial the for commercial discuss fourth revenue follows. cases metrics the of next users down and XX, quarter compared were and XXXX paid

QX, SkinTE While paid revenue number is of causes time, revenue size sensitivity even in QX number ramp is size sensitivity cases the extent to the size than continues to To should wound the was to wounds paid the which decrease. of in QX relation cases this grow to quarter-to-quarter increases higher cases were cases revenue. solely in paid in over though paid infancy number quarter-over-quarter, of Consequently, relation lower from the higher wound treated. its attributed a in the of treated which to

of half that the grew XXXX. note XX% grew first leadership revenues the while It of is changes cases SkinTE XX% June important XXXX to paid to compared since in

on growth Our case focus both user in traumatic and chronic and driving remains wounds.

striving to growth converting for them in users repeat then We new and users. consistent are

have biggest opportunities with we number momentum with to are that where believe continue We of multihospital approvals. system-wide networks a already gained our

an you takes care. time, on we when are driving wound mentioned As our call, last in earnings introducing innovative product adoption particularly

we factors have to reason a in such metrics in continue to of seasonality, quarterly we reimbursement. variability these number past, and due and as the stated expect this For pricing, as

well-defined critical. We and product providers process also acknowledge that a SkinTE to is a educate differentiated is to establishing unique

we rates wounds. the a the So about what large adoption faster noticed quarter we doing in Midway First, headwinds are fourth usage to and learned pricing. have we to what be decline it? through in

larger received the played positive seasonality despite hindering identified we of the wounds was a reason treat feedback reuse. from for While main more the SkinTE, that was with and providers as we treating patients outcomes, desire to the cost role, believe

Although were SkinTE quarter, unpaid them several with cases. wounds were product evaluation during the large many treated of

a which we out this will be finalizing to new result, As pricing issue rolled structure address soon. are

As benefits that types. This wounds recall, of new in you the these segment issue usage in consistent June may pricing similar adoption address of modified in we market. structure structure believe of XXXX to wounds. for pricing more in in our similar adoption can repeat smaller SkinTE wound We yield a chronic larger our in resulted

reimbursed as certainty a assist staging for and positive navigating provide to this guidance existing new we engaged order SkinTE SkinTE to experts we recently level materials see with sales and in development force certified providers our to to with codes services. it Two, reducing Consequently, using should be coding coding modifiers independently coding more as and skin very our how full clarity thickness more reimbursement. SkinTE. providers, to is diplomat for introduced appropriate SkinTE. In experts assess for produce as they that landscape will grafts, for [ph] These the We provide reimbursed determined appropriately reimbursement. for reimbursement

payers the We Health healthcare end, is that appreciate cost VLU and secondary SkinTE clinical cost-effectiveness and endpoint ongoing in DFU Economic trials. the providers. using showing Data. systems, a benefits value To understand our and to of

to the time to SkinTE customers of operating in a believe total working identify per shorten cost addressing care are using we adoption. patient with length Additionally, result help stay SkinTE. as these faster headwinds large of should We savings room support

key Hague to to like Richard an achieve to over clinical the near we milestones future and and as current provide well achieved the call as turn expect organization I'd as in have Richard? Now, on update an future. to trials

Richard Hague

Thanks David.

of in top clinical various priority the wound the support us. use described, data SkinTE for a types As to David generation of remains

accomplished payer to Our goal of care physician continue heal as of to world RCTs, ultimately results data. a adoption strategic data, wounds SkinTE hard and broad This SkinTE reviewed surgical, retrospective of order and position be traumatic in physician clinical the wounds. peer and chronic through the complex and standard combination real to published to driven utility for to will and perspective drive is and validate of burn

results to our goal share enrolled our for updates. pre-specified be present this enrolled analysis in before the now the the submit chronic of our targeted and expect at analysis mid-May XX spring am this soon to publication remaining SAWC two we meeting patients we the very end for of has after. wounds, interim We RCT DFU March. Diego and plan San the pleased is in to of data the I following to patients ongoing XX with Starting

for enrollment be full study this expect year-end. reached by to We

target by VLU achieve enrolled we of believe our year-end. patients currently are enrollment XX patients has we Our XX and on to schedule RCT interim

for submitted data recently our be VLU reported to DFU we very submitted was data pilot expect Additionally, and shortly. the pilot previously publication

and health traumatic working surgical in economic we with and the generate data. efficacy and centers use to health extended valuable wounds, key are support healthcare To providers

As for submitted SkinTE I'm following. publication. combined report two is series recently generated to a result, of A patients pleased case medical pediatric well-known the centers by

patients. weeks a report submitted recently incident. deep of from With failed to soldier in wound SkinTE An that case line university particularly paper the recovers soldier traumatic he product. and were the was informed SkinTE hospital We in prestigious trauma at experience other injured in This initially highlighting sustained expected due when nine fact was his that to return compelling active-duty to journal number another he injuries to for and to recently. major a active a is the the closed publication was duty submitted independently has utilizing a their of heal wound competitive duty with initial

to the of Lastly, for lower we expect in second prospective have and trauma year. enrollment finalized the half study a extremity protocol begin

was scheduled podium mid-March Burn trial which in in take Orlando. Association a accepted meeting the American to related data In the our from was burns, abstract for presentation place at head-to-head in

was informed may conference a recently However, were that this be virtual as we restructured conference. but canceled,

course. a arm a the IRB efforts work updates burns be single and study space, we provide to for the for conference publication review due We our submit final further To protocol to Separate to QX. we from from will abstract KOLs perspective study several in submitted it continue expect in to burns this with plan soon. in finalize [ph]

notably SkinTE I'd presentation at the slide, seven but spring Finally share to like accepted the to current seven for following. were the most on Conference. that SAWC are listed are highlight abstracts we abstracts excited The very

First is Armstrong. presented diabetic by trial David homologous with the randomized construct treatment a foot a to novel ulcers skin autologous Dr. controlled of evaluate

Overall being novel and our that generated industry retrospective ulcers of are and autologous coming and data a SkinTE off M.D. is the this construct Second paying and pressure implemented the data a we in us with near series Shenaq, presented quality adoption half data be we supporting in peers. extremely homologous to by to of in that drive other XXXX is clearly are expected SkinTE We strategy volume recognized case quarters. treated Deana broad confident published by in allow skin second the with ultimately we pleased that generation of physician multicenter should the believe is the payer future and

like our now to development would to I transition and research activities.

last SkinTE projects are quarter, priorities. development reported related two that we As had top

First any a cryo cryopreserve original to This of point progressing project same months planned. date. harvest product to the us SkinTE extension the is as from which on additional six patient our line to deployments a at allow final certain single SkinTE for harvest amount up from will allow

customers to expect quarter. and existing to new third concept introduce new in We this the

for chronic prefer offering of the We to damaged deployment but an wounds without wounds may physician in deployments or regimen. patient revenue valuable be We susceptible may to normal do healing due patients incremental location cryopreservation size, a multiple course and staged and noncompliant of will charge additional do the not their anticipate SkinTE become due patients ease with a to generated harvest. expect patients to circumstances, process, being to during that future where this plan

The to phase first firm outside finalize an in-house development for continue point-of-care to of make design main SkinTE be collaborating deployment our to allowing following in we with of engineering is which processing attribute the the to user in our of initial SkinTE SkinTE team used Secondly on gather is harvest. the project of objective the designs that development We're bedside of progress the midst and data. move device. immediately will prototype this to

the of QX complete in of to expect this XXXX. We phase development

on I our node Georgia. Lastly, update manufacturing in brief the a like progress to would Augusta, of provide

then will the We and construction final equipment are in phase processes. and of begin validating

new early is goal QX. to facility. Our the by be live area hospitals a to smooth of collaborating the In we parallel, go use and with transition will to ensure ACPs

making to are of related the I potential Overall, SkinTE encouraged progress that to we place very the patient strongly strategy product SkinTE. have in maximize the with and I appropriate remain development. full we data believe

over update. to turn Now I'd to like the financial for a Paul call Mann

Paul Mann

Thank you, and everyone. Richard, good morning

in revenues, quarter reported fourth products from revenues XXXX service contract refer which million approximately in $X.XX $XXX,XXX. most early services the revenues the we we which products refer revenues Wound and size revenue SkinTE, For Revenues variable to organization, were metrics our growth stages. $XXX,XXX therefore services XX-K were we in in from the includes as from to the as quarter total from these during XX-K. and and which and

case wound our the wound size with With treated base accounts admissions volume, within quarter-to-quarter and our average change traumatic current in can fluctuations SkinTE. user significantly

individual of by wound and accounts to expect adoption revenue and per begin that wound continues space. reflect case less grow seasonality the to as become to We these average dictated broader care in fluctuations gradually quarter-to-quarter size in

in For million during quarter. XXXX month, used cash million higher the or per $X.X third the quarter were fourth which cash than approximately in operations is $XX the use operations

As quarter. third employment I our made payments severance our number highlighted whose company payments CEO were on quarter the nonrecurring fourth cash XXXX. third these to with during income ended items statement the the related August to XX. to during accrued that accrued the of quarter the during a former expenses to related The call,

we of XXXX second we operations quarterly from look During and witnessed during expect first fourth cash or not third XXXX quarters the flow more quarters to what in XXXX. like would the

team discipline. fiscal executive three key of As the previously mandates the is of one mentioned,

an second these the during impacting reduction cost the XXXX, in evaluating initiatives we provide we QX without cash of completed May. number a burn the the business. currently core to of competence update half During of reduce call are measures, on additional we'll

and on February with million public million investments our cash On offering We XX, of underwritten balance after sheet. short-term operating estimated additional quarter equivalents $XX.X completed securities $XX.X we fourth finished the and cash, XXXX an of expenses. our we raised

months. capital raise beyond the liquidity this operations sufficient fund will on give XX sheet next us Following to balance the

chose time have Many did. asked the investors to why we capital raise we at

a the We XXXX be a near, it aren’t prudent going there during the and balance and or predict to in direction potential long-term volatility were number these potentially markets. did could recognize that the medium financial We try to maintain sheet strong would of we stock of markets times. create that events believe during turbulent

the steadfastly saying the we by commercialization on SkinTE close second half encouraged we I'll focused discipline we of are XXXX. and that the and remain fiscal by process during have of made

to concluding like to I now would Seaburg some call the back for David over turn remarks.

David Seaburg

Thank three discussed the call. points most I'd like to important today's you, of Paul. recap on

to we we taken a increased SkinTE have we to are based steps commercialize stronger First, position opportunities adoption. today believe in for identify on

to of clinical we upon awareness build to the increased to forward results several near-term and upcoming support continue execution Second, portfolio catalysts, we continued interim SkinTE. for presentation market will namely publications expansion our look for DFU potential of which several adoption expect PolarityTE's the trial, and patent the

constructive XXXX the believe be payers treated successful we of and with of studies evidence, numerous additional to our of our with were for adding initiation growing scientific and SkinTE patients strong clinical recognitions. Third, industry Hundreds and outcomes, awards discussions providers. body in will

We long-term to on taking support and payers continue other proud commercial Instead for treat our We positive hard while our right savings the given potential efficacy we generating success incremental any and SkinTE. we in considerable lives, grateful and delivering and of on path the to most significant wounds outcomes believe to patients SkinTE failed. returns impact we providers deliver SkinTE to had the a accomplishments measure solution I it believe I our to adoption sometimes steps for patients' measure treatments many generate don't the shareholders. the provide has on positive are of long-term am has so will stakeholders. to quarter. for I by have are are that believe value where to

add for our call open you determined Thank of hard-working want dedication am like all I questions. I our your employees. PolarityTE. joining to it for incredibly just I'd proud for now up Thank today. that all to to Finally, you and

Operator

first DeGeeter with Thank you. Our Oppenheimer. [Operator question Instructions] from Kevin comes

Kevin DeGeeter

guys. see, Thanks of on what be, tend wound sort Can to see morning, size should just for my good comment the you threshold which Hey, taking questions. under resistance model? you you pricing some current

David Seaburg

Hey, the is This Thank Kevin. how you? David joining are you for call.

towards catalyst a there know, really emphasized larger don’t XXX XXX is Kevin say I'd important it a on or really and wounds You is is over think square that for necessarily I upward just, this centimeters, we call I think the pricing us. threshold.

the customer base The to weeks. rollout, once, a early a really all based do strategically. the at and we drive did going contact the is the just and deep be so out we believe that we're was. we dive it having We to price. our believe the national around be within this asked really and going next a going was what this with some plan hindrance with help that polled And staged going constant them through but feedback that response we went It won't conversations providers several overwhelming is be in we to on questions and into rolling are really adoption. to are we're And

Kevin DeGeeter

of course least of average do XXXX XXX,XXX good quarters, of SkinTE wound new now sort through or lower central XXXX? that could that first size, the revenue of under the yes that about was about in terms metric think to at think plan per a we you through think is revenue as way half And per implant, around the trends pricing be

David Seaburg

we in that's see of predicated wound that adoption going that But this the really depends could do larger variability adoptions near adoption that the – pricing in size but can Well see structure, over that wounds a the we or it have we time see if obviously as go I higher. wounds But that size. on up in larger I in term in reduce. is lot wounds pick I more we imagine think over we can wound long the term it again think and based is treat, we number expectation chronic to see on that on it, all

Kevin DeGeeter

just one Can study and you right, extremity provide more bit last you out? lower in the are little about one how then get just thinking me, I'll study you a design for the All then commerce back from details of called queue. that

David Seaburg

Sopko Yes, Nikolai sure, here to is along I'm put us. going on, with he right Nik?

Nikolai Sopko

Kevin. it complex trial, more a is we are and lower Yes, Hi, wounds. great specifically at for question looking the extremity

So wounds acute, tendon, be with of such traumatic more reconstruction. and but complex bit necessarily these exposed these are trials, that as bone require extensive might in and some structures a muscle other aren’t chronic treated our wounds quite typically

of trial the such on treatments reconstruction can design complex at wounds, the focusing structures treatments to which do as we're require but to flap patients complex so really ability or of oftentimes And to and those cover for that not multiple surgical looking SkinTE only those those close so.

Kevin DeGeeter

All right, for thank you that.

Operator

We our Fitzgerald. will Kristen next from question Kluska with Cantor take

Kristen Kluska

taking and Hi, for my good thanks morning, questions.

higher And here pricing The surgeons larger some front? of you and initially further sell require applications is, for that used is the price considerations product feedback numerous first could with up time discuss may can wounds? out in trying the over that a place where as some using not one products for versus typically work are is spread the to pricing the future the

Richard Hague

from exactly when them facility there is And reimbursement to yes, appreciate one and patient sizes Richard quarter appropriately DRG working we're that hi wound are has is look at on. the it are get at we're What with pricing. schedule. two trying the certain process is maximized that And looking patient here. at that's each are you and looking types, things DRG is certain Kris, and reimbursement address, they to a can I an ensure really appropriate facility that so right. education that coding Yes, you we the the DRG

that appropriately that wound. for make size obviously in our second that sure price pricing it fits is to DRG product we when And that

great So - that's it facilities to approaching in number we require are your And going single others. a how of second products that multiple really cost care terms a in story with be we SkinTE. is different being We are certainly of of to than lower certainly applications, total and point per we one believe more have this. application tell terms product to sophisticated believe patients the about

higher However, initially upfront and products. was competitive a application price our per than

So the addressing ensuring the a facing that. bit SkinTE. we're as sticker for But care, now a favorable at were facilities that of But we is there certainly with total facilities. sophisticated some that said cost looking with we're I also, around we're shock more having conversations was of which whole

Kristen Kluska

conversations Okay, prepare think particularly what your thank with various your view few results? of And data compelling you. important measures based they're committees, announce you looking view, the to the do had VAT most you in within some DFUs, that And next months, you've they'd the are as trial and as what on surgeons for?

David Seaburg

for Kristen, our anticipate for the that you And, our know, presenting analysis spring do thanks the foot ulcer for interim SAWC planned conference. we is diabetic Hi, trial question.

other in to data, coronavirus rescheduled to that to about recent However, medical providers with might we've that we setting, concerned ability setting. the use conferences. the about conference show SkinTE its like had many effectively that which of from data outpatient then in the a be of really get designed But are and seeing feedback clinical lot used and that favorable ability efficacy, the and is

Richard Hague

the easier there process number be the That's and that's that across key one goal library we're do goal our basically And data. here. building types, the here. too is our that various will the more back that published we the wound of can think I

Kristen Kluska

and any new to but the discuss you've repeat you've any you've on And and data trends specialists the of see wanted And who product been observed users, currently has then I the collecting the that those can number different you particular product, are that? great. number seen how the if in using if Okay, changed trial in the number of been and tracking using institutions stage? including

Richard Hague

mostly of track information, terms the of focus of because the total drives that the level, we on provider number In product. but that institutions, really we certainly adoption

that are really So, the we growing definitely about we institution, number, of within while number physician care that.

hospital go is real Our into deep these to networks. goal

we'd don't number so part expect number same would second the to as that sorry, we of hospitals of of we And add So think one. I we question? the your that's grow, that want I'm the physicians number

Kristen Kluska

Just relates the any trends to the it as particular using different specialists who product? are

Richard Hague

- with Well, see about of of trauma certainly, broader number the of cases. XX-XX as as now, looking right David XX I'd split to we at space, we're on we're terms we're focusing so being specialists said chronic trauma now, say, going we're in group Right a chronic a more versus there. seeing

and in general that more see see going the trauma in vascular, when the to most space you're you're space, general into you So surgeons vascular and and parts. podiatrists well. plastic going for that to space, obviously, move as And

range a to space. it's pretty seeing, and broaden go as continue that trauma that the So into we're now, right we trying broad to certainly we're

Kristen Kluska

for you question. thank taking Great, my

David Seaburg

you. Thank

Operator

with question next Our Northland from comes Securities. Carl Byrnes

Carl Byrnes

and bump size terms for is, question towards to thanks that said relatively regards business? weighted looking on out Great, I And would to in would larger treated you question. would it wounds? - of that be anticipate the anticipate the of you how imagine you online to a my facility quarter, taking come the how guess you then, out expect of to frame wounds With do overall third immediately, and Thanks. to another would roll relative I way

David Seaburg

this and of centers if specifically Yes, and of last And will been engaged medical the us main they've in that actually repeated so, been reuse. we've have real the those in half physicians mean I situation. told a larger weeks, for this you dozen networks, in has engaged we actually productive couple and addressing conversations pricing time hindrance our conversations extremely as we've are

lined they So out treat if they could favorable. examples pricing patients was had doctors we've in had call the specific that more which up several

expect size, hopefully, terms that do this we QX term to So be we of very, where in in a but relatively always do expect start to wound to near But hard very that will see it's increase. predict. size wound inflection to

Carl Byrnes

you. Thank Great.

Operator

next from H.C. We'll Sean Wainwright. take with Lee our question

Sean Lee

question. alternative for With canceled lot the going Hi, presented SAWC, at on? my light plans of guys. well to Thanks have gets taking epidemic conference in be in that as a have case data made of we expected you the

Richard Hague

looking Sean postponed soon they hi, unclear can question. that the how at organizers to about. presentation, week data virtual very obviously example, our just They conference plans It's great just until if to been couple canceled that discussions potentially contingency of put if and advanced the there's we're would will there. that know conference, conferences, additionally, year. data virtual - having the provide themselves so something help Yes, ABA sort be that's have it's own just But a later others days sort and ago. of get exciting able but out together, us next all the And a we're for needed we several that this we already SAWC, let as a concerned know that for as about about

Sean Lee

you many have of of efforts cancellations? any these to changes made in marketing light Also, your

David Seaburg

active is Yes, the conferences certainly. present some field in I different reps Nik to two mean, those. possible that did there of doing at we're One sales as And this in given plans as as to know, the the you be approaches the restrictions. be we're being that described, - have parallel. to have is are we obviously canceled,

certainly an point. that's important So

important. territory So as as touch is in points critically we many directly can healthcare get the providers the with

in be as And certainly Nik going is, we're unlike to other companies, second described the like marketing to virtual efforts. - having engage

looking setting. that broader country like might programs terms that what at have we a in could and on impact virtual the And so like, across how a look putting of in we're

Sean Lee

color. That's additional the all for I Thanks have.

David Seaburg

you. Thank

Operator

And we go question, now take web a please will Mr. Haerle, ahead.

Rich Haerle

you Thank things the you, operator. for if prepared how is, happen from disruptions is happen? travel from issues Wainwright. The The are that question we have H.C. are way could were RK with chain that next with supply to question progressing,

David Seaburg

when David, SkinTE, I at people chain supply I to think for product our this issues you our product we the process trained that and or us, mean, are making It's really the that way people it's sure process product look the safe. and are

issues necessary to this we and sure supply had from are the process, as at haven't to curve at far perspective. occur. separate current disruptions make processors taking that of definitely that no we're we are safe don't that are them general our issues any really hiccups steps needed interact distance time, as prevent that to just standpoint medical making allow there. And very the make could to we ahead sure them the supplies that sure a But keeping there to of we from So, necessary

Operator

at time thank there you. questions. are Thank And We for no your further participation. you this

this You may call. you. Thank from now disconnect

Polarityte (RGTPQ) 12 Mar 202019 Q4 Earnings call transcript